Paul Cottu is currently Deputy Head and Head of the Day Care Clinic in the Department of Medical Oncology at Institut Curie, Paris, France. Dr. Cottu completed his training in medical oncology at the Paris Diderot University and became an associate professor of medical oncology, then a full-time physician, at the Breast Disease Center at Saint Louis Hospital, Paris. In 2006, Dr. Cottu joined Institut Curie, his present position. His research focused first on high-dose chemotherapy in early and advanced breast cancer, and then on endocrine resistance in luminal breast cancer as well as metastatic breast cancer biology. Dr. Cottu completed his PhD thesis in 2015. His research group developed endocrine-resistant patient-derived xenograft (PDX) models that are now widely used in the preclinical setting for early drug development in endocrine-resistant breast cancer. Dr Cottu is currently focusing his research on neoadjuvant trials in luminal breast cancer with CDK4/6 inhibitors, and is also in charge of the development and implementation of joint Institut Curie/Gustave Roussy Cancer Campus breast cancer guidelines. He is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and of the Bureau of the Unicancer Breast Group. Graduated in Medicine from the Faculty of Medicine of the University of Porto, in July 2003. Graduated Hospital Assistant in Medical Oncology at the Portuguese Institute of Oncology Porto Francisco Gentil since 2011. On September 25, 2011 obtained the European Certification in Medical Oncology from ESMO (European Society of Medical Oncology). In July 2019 concluded the Doctoral Program in Medicine and Molecular Oncology at the Faculty of Medicine of the University of Porto. Collaborates in the Master in Oncology ICBAS – IPO Porto (being responsible for the Clinical Oncology Curricular Unit) and with the Portuguese School of Oncology of Porto (EPOP), among other pre and postgraduate training activities. Researcher at the IPO Research Center in Porto (CI-IPO), having collaborated in several clinical trials. Author of several articles published in national and international journals and book chapters. Areas of interest: breast cancer, head and neck cancer, cancer pain, nutrition, supportive care, screening/early diagnosis and survivors.

Dr Maria Piperis completed her undergraduate studies at Columbia University, NY in 1999, where she was born and raised. Medical Studies were completed in Greece in July 2002, her country of origin. Following that, specialty training in Radiation Oncology was completed by 2008, and a PhD on Breast Cancer radiotherapy and radiation pneumonitis was obtained in 2011. A Fellowship was also completed in NY Weill Cornell University on Breast Cancer advanced radiation therapy techniques. After working in the public sector and with a special interest in hormone sensitive cancers and the central nervous system, since 2014 she has worked in a private clinic as a specialist in radiosurgical procedures and breast and prostate cancer mostly. Since 2019 she has been Assistant Director of her department. At the time that the manuscript was prepared, Alexandros Sagkriotis was the RWE Head in Novartis Oncology Europe. He has received Bachelor's degree in Mathematics from the National and Kapodistrian University of Athens, Greece and two Master of Science degrees in Biometrics from the University of Reading, England, UK and in International HTA, Pricing and Reimbursement from the University of Sheffield, England, UK. He is current working in Gilead Sciences Europe Ltd as Senior Director, RWE PAS Lead-Oncology. He is interested in RWE / RWD, predictive analytics, digital and SML projects.

© 2022 The Authors. Published by Elsevier B.V.